Published in Proc Natl Acad Sci U S A on September 06, 2002
Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC (NA_00092076) | NCT02259621
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) | NCT02846376
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | NCT03918252
PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer (PICARES) | NCT03971214
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A (2004) 4.75
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol (2015) 4.68
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia (2006) 3.54
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature (2016) 3.18
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood (2007) 3.00
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 2.70
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2014) 2.61
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood (2009) 2.54
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50
Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A (2005) 2.49
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 2.41
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood (2008) 2.41
Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res (2012) 2.39
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med (2005) 2.32
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24
Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med (2015) 2.12
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci U S A (2008) 2.03
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer (2014) 1.92
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med (2003) 1.92
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest (2011) 1.91
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90
NFATc1 regulates PD-1 expression upon T cell activation. J Immunol (2008) 1.81
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med (2011) 1.77
Recent developments in cancer vaccines. J Immunol (2011) 1.76
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther (2015) 1.73
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Overcoming T cell exhaustion in infection and cancer. Trends Immunol (2015) 1.72
Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest (2004) 1.71
Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol (2012) 1.71
Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med (2012) 1.71
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest (2015) 1.67
FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer (2008) 1.63
Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget (2015) 1.62
Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther (2014) 1.58
Harnessing the immune system to treat cancer. J Clin Invest (2007) 1.57
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med (2013) 1.48
Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology (2012) 1.48
The role of B7 family molecules in hematologic malignancy. Blood (2012) 1.47
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother (2011) 1.47
Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov (2013) 1.46
PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One (2015) 1.45
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell (2014) 1.45
Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical research. Proc Natl Acad Sci U S A (2015) 1.45
Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One (2013) 1.44
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 1.44
Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A (2017) 1.43
PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest (2013) 1.42
Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med (2014) 1.40
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res (2014) 1.40
Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res (2008) 1.38
B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One (2013) 1.38
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer (2015) 1.32
T-cell exhaustion in the tumor microenvironment. Cell Death Dis (2015) 1.32
Inhibitory receptors on lymphocytes: insights from infections. J Immunol (2012) 1.30
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood (2012) 1.30
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol (2009) 1.28
Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A (2015) 1.27
Targeting metastasis. Nat Rev Cancer (2016) 1.26
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A (2015) 1.26
B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol (2008) 1.25
Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther (2015) 1.23
Single-cell analysis tools for drug discovery and development. Nat Rev Drug Discov (2015) 1.23
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med (2011) 1.23
Role of PD-1 in HIV pathogenesis and as target for therapy. Curr HIV/AIDS Rep (2012) 1.22
At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol (2013) 1.21
T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther (2010) 1.17
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology (2014) 1.16
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis (2015) 1.15
Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol (2014) 1.13
PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One (2014) 1.13
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol (2016) 1.12
A dimeric structure of PD-L1: functional units or evolutionary relics? Protein Cell (2010) 1.11
Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother (2012) 1.10
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther (2010) 1.10
The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol (2011) 1.10
VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Res (2014) 1.09
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 8.31
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 6.79
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 6.73
Tumor antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 6.16
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol (2001) 5.17
Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol (1998) 4.14
ICOS is essential for effective T-helper-cell responses. Nature (2001) 4.01
The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med (1991) 3.22
Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today (1997) 2.89
Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett (2002) 2.80
PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol (2001) 2.71
Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J Immunol (1996) 2.70
The complexities of T-cell co-stimulation: CD28 and beyond. Immunol Rev (1996) 2.08
Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today (1997) 1.91
Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J Immunol (1995) 1.68
Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens. J Immunol (2001) 1.59
The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur J Immunol (1998) 1.43
Synergistic effect of interleukin-15 and interleukin-12 on antitumor activity in a murine malignant pleurisy model. Cancer Immunol Immunother (2000) 1.23
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol (2007) 6.24
Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci U S A (2004) 5.93
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res (2004) 5.59
Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell (2004) 5.50
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer (2010) 5.05
Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer's patches. Science (2009) 4.80
Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. Int Immunol (2002) 4.66
The PD-1-PD-L pathway in immunological tolerance. Trends Immunol (2006) 4.52
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol (2005) 4.01
Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev (2004) 3.95
AID is required for c-myc/IgH chromosome translocations in vivo. Cell (2004) 3.89
PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol (2002) 3.78
Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat Immunol (2002) 3.75
Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med (2007) 3.70
AID mutant analyses indicate requirement for class-switch-specific cofactors. Nat Immunol (2003) 3.69
Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature (2002) 3.60
Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora. Science (2002) 3.58
PCR-mediated generation of a gene disruption construct without the use of DNA ligase and plasmid vectors. Nucleic Acids Res (2002) 3.47
Constitutive expression of AID leads to tumorigenesis. J Exp Med (2003) 3.16
AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science (2002) 3.09
PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med (2003) 3.05
Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep (2008) 3.03
Regulation of alphabeta/gammadelta T cell lineage commitment and peripheral T cell responses by Notch/RBP-J signaling. Immunity (2004) 3.01
Uracil DNA glycosylase activity is dispensable for immunoglobulin class switch. Science (2004) 2.93
Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett (2002) 2.80
AID is required for germinal center-derived lymphomagenesis. Nat Genet (2007) 2.79
Forebrain ependymal cells are Notch-dependent and generate neuroblasts and astrocytes after stroke. Nat Neurosci (2009) 2.74
Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1. Proc Natl Acad Sci U S A (2004) 2.69
Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med (2003) 2.66
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med (2003) 2.65
Intestinal IgA synthesis: regulation of front-line body defences. Nat Rev Immunol (2003) 2.62
Medullary thymic epithelial cells expressing Aire represent a unique lineage derived from cells expressing claudin. Nat Immunol (2007) 2.61
B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity (2004) 2.60
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50
Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A (2005) 2.49
Sex determination in the social amoeba Dictyostelium discoideum. Science (2010) 2.42
SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet (2007) 2.39
The AID enzyme induces class switch recombination in fibroblasts. Nature (2002) 2.28
Activation-induced deaminase (AID)-directed hypermutation in the immunoglobulin Smu region: implication of AID involvement in a common step of class switch recombination and somatic hypermutation. J Exp Med (2002) 2.18
Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice. Cancer Cell (2003) 2.11
Separate domains of AID are required for somatic hypermutation and class-switch recombination. Nat Immunol (2004) 2.06
Regulation of marginal zone B cell development by MINT, a suppressor of Notch/RBP-J signaling pathway. Immunity (2003) 2.03
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci U S A (2008) 2.03
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol (2004) 2.02
Regulation of lymphocyte development by Notch signaling. Nat Immunol (2007) 1.96
New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol (2002) 1.92
Periodic signaling controlled by an oscillatory circuit that includes protein kinases ERK2 and PKA. Science (2004) 1.90
A transcriptional profile of multicellular development in Dictyostelium discoideum. Development (2002) 1.88
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med (2011) 1.80
The canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. Dev Biol (2006) 1.80
Discovery of activation-induced cytidine deaminase, the engraver of antibody memory. Adv Immunol (2007) 1.80
Hes1 directly controls cell proliferation through the transcriptional repression of p27Kip1. Mol Cell Biol (2005) 1.79
Rap1 GTPase: functions, regulation, and malignancy. J Biochem (2003) 1.78
Pyramidal neurons of upper cortical layers generated by NEX-positive progenitor cells in the subventricular zone. Proc Natl Acad Sci U S A (2005) 1.77
Mice carrying a knock-in mutation of Aicda resulting in a defect in somatic hypermutation have impaired gut homeostasis and compromised mucosal defense. Nat Immunol (2011) 1.74
RBPjkappa-dependent Notch signaling regulates mesenchymal progenitor cell proliferation and differentiation during skeletal development. Development (2010) 1.72
Role of AID in tumorigenesis. Adv Immunol (2007) 1.69
Learning and memory deficits in Notch mutant mice. Curr Biol (2003) 1.68
IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol (2011) 1.64
Impaired T lymphocyte trafficking in mice deficient in an actin-nucleating protein, mDia1. J Exp Med (2007) 1.64
Apex2 is required for efficient somatic hypermutation but not for class switch recombination of immunoglobulin genes. Int Immunol (2009) 1.62
Inhibition of Notch/RBP-J signaling induces hair cell formation in neonate mouse cochleas. J Mol Med (Berl) (2005) 1.61
Identification of the ubiquitin-protein ligase that recognizes oxidized IRP2. Nat Cell Biol (2003) 1.61
Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL. Blood (2010) 1.60
Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res (2004) 1.60
Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother (2006) 1.59
Changing patterns of gene expression in dictyostelium prestalk cell subtypes recognized by in situ hybridization with genes from microarray analyses. Eukaryot Cell (2003) 1.55
Cutting Edge: Ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J Immunol (2002) 1.55
The interleukin-4 enhancer CNS-2 is regulated by Notch signals and controls initial expression in NKT cells and memory-type CD4 T cells. Immunity (2006) 1.53
Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol (2011) 1.50
Multiple roles of Notch signaling in cochlear development. Dev Biol (2007) 1.48
Bromodomain protein Brd4 binds to GTPase-activating SPA-1, modulating its activity and subcellular localization. Mol Cell Biol (2004) 1.47
Notch/RBP-J signaling regulates epidermis/hair fate determination of hair follicular stem cells. Curr Biol (2003) 1.46
Rap1 functions as a key regulator of T-cell and antigen-presenting cell interactions and modulates T-cell responses. Mol Cell Biol (2002) 1.46
Recombination signal sequence-binding protein Jkappa alters mesodermal cell fate decisions by suppressing cardiomyogenesis. Proc Natl Acad Sci U S A (2003) 1.45
De novo protein synthesis is required for the activation-induced cytidine deaminase function in class-switch recombination. Proc Natl Acad Sci U S A (2003) 1.43
B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat Immunol (2009) 1.41
Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant (2004) 1.40
Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells. J Immunol (2013) 1.39
Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology (2008) 1.37